Introduction
Gene transduction in the cardiomyocyte has always represented a major technical difficulty that has hampered detailed study of specific biochemical pathways in this cell type. In fact, conventional methods such as calcium phosphate transfections and liposome or lipofectamine-mediated gene transduction work poorly in cardiomyocytes. While these methods are useful for gene reporter studies, they are of little value when the aim is to introduce a gene into a substantial percentage of cardiomyocytes. For this purpose, adenovirus (Ad) type 5 is the preferred vector. 1 However, drawbacks of Ad vectors are their generation process, which is difficult and lengthy, and their immunogenicity, which prevents their use for long-term in vivo experiments. 1 Another vector, the adeno-associated virus (AAV), is suitable for in vivo myocardial gene transduction, because of its low or absent immunogenic potential, 2 but the use of AAV for in vitro studies is limited by the low gene expression (less then 10% of cardiomyocytes in culture) achieved during the first weeks of infection. 2 Thus, although adenoviral vectors have contributed to the advancement of studies in cardiovascular pathophysiology, they are still not optimal for both in vitro and in vivo studies.
Retroviridae are RNA viruses whose RNA has to be reverse transcribed into DNA in order to be integrated into the nucleus. 3 g-Retroviruses, represented by Moloney virus, and lentiviruses, represented by HIV, are genuses of the Retroviridae family. Moloney virus requires nuclear breakdown, and therefore M phase, in order to be integrated into host genomic DNA, while lentivirus can enter the nucleus even without mitosis. 4, 5 The ability of third-generation lentiviral vectors to infect growth-arrested cells (such as cardiomyocytes) has been shown in principle, 6, 7 but their transducing efficiency has never been analyzed in detail. Moreover, there are no reports demonstrating whether these vectors can be used for myocardial gene expression in vivo. Recently, a new variant of third-generation lentivirus (the 'advanced' generation) has been described 5 in which sequences of the pol gene of HIV-1 (cPPT) and of the post-transcriptional regulatory element of woodchuck hepatitis virus (WPRE) have been inserted. cPPT is a cis element, which has been associated with more efficient gene expression in growth-arrested human hematopoietic progenitor cells. 5 Here, we describe the use of 'advanced' generation lentiviral vectors as an extremely efficient and simple method of inducing gene expression both in vitro, in neonatal rat cardiac myocytes and in vivo in the adult rat heart.
Results
'Advanced' generation lentivirus efficiently transduces neonatal rat cardiomyocytes Neonatal rat cardiomyocytes (2.5 Â 10 4 /well) were exposed to 1 ml supernatant containing the 'advanced' generation lentiviral vector (100 ng p24) carrying a GFP reporter gene. Cells were exposed to lentivirus for either 2 h or ON and GFP expression assessed by FACS analysis 12 or 48 h later (Figure 1a and b). In cells exposed for 2 h, the percentage of GFP-positive cells rose from 63% at 12 h to 72 % at 48 h. In cells exposed to the virus ON, the percentage of infection increased from 64 to 84% at 12 and 48 h, respectively.
To determine the infection efficiency of this viral vector, scalar cell concentrations were exposed to the same amount of virus (100 ng p24/ml). The percentage of infection was evaluated by FACS analysis after exposing the cells for 2 h and detecting GFP after 48 h (Figure 1c) . Results show that with this concentration of virus, infection was highest (470%) when 2.5 Â 10 4 cells were used. Viral stocks concentrated more than 100 ng of p24/ml produced toxicity.
In some experiments, expression of the muscle-specific marker, myosin heavy chain (MHC), was detected by indirect immunofluorescence using a monoclonal antibody, MF20, and visualized by a commercial TRITClabeled goat-anti-mouse-IgG secondary antibody (Sigma). Double-labeled cells represented infected cardiomyocytes (Figure 1d) . Thus, these experiments show that the lentiviral vector, at a concentration of 100 ng p24, can efficiently infect neonatal rat cardiomyocytes in vitro. lentivirus. In fact, the 'advanced' generation lentivirus showed a four-fold increased efficiency at 100 ng p24/ml as compared to the third-generation lentivirus, and remained at least three-fold higher at lower dilutions (Figure 2a and b).
Role of promoters in mediating the transduction efficiency of lentiviral vectors
We tested the effect of two different promoters in determining gene transduction in cardiomyocytes. Lentiviral vectors containing either the human PGK or the CMV promoter in the expression cassette were produced ( Figure 3a ). Cells were exposed to virus for either 2 h or ON and FACS analysis of GFP expression performed 48 h later. Results demonstrate that the viruses with these two different promoters had comparable efficiencies of infection. In fact, the percentage of infection reached more than 75% using viruses containing either one of the two types of promoters in cells exposed ON and approximately 70% in cells exposed for 2 h (Figure 3b and c). The efficiencies of infection were similar also when using diluted supernatants. Mean fluorescence intensity (MFI), a parametrer which corresponds to the strength of the promoter, was also measured. MFI was higher using the lentiviral vector constructed with the CMV promoter with respect to that with the hPGK one ( Figure 3d ).
In vivo efficiency of lentiviral vectors
Once the efficiency of lentiviral vectors was established in vitro, experiments were performed in order to address whether they are able to induce efficient and long-lasting expression in myocardial cells in the intact animal. For this purpose, the hPGK promoter variant of the 'advanced' generation lentivirus was used. A previous report on third generation lentiviral vectors in CNS infections demonstrated that lentiviral DNA had to be integrated into the host's genome for gene expression to take place in long-term in vivo experiments. 8 Thus, we used the same vector without integrase (intÀ), an enzyme critical for integration of lentiviral DNA with that of the host, as a control. The ability of integrase + (int+) and -(intÀ) lentiviral vectors to infect and induce persistent GFP expression was first tested on the TF1 leukemic cell line. These cells were selected since they are suitable for long-term (more than 2 weeks) experiments in vitro. FACS analysis after 48 h showed that more than 80% of TF1 cells infected with int+ 'advanced' lentivirus scored positive for GFP, while only around 40% of cells were infected with the intÀ form. After 15 days, virtually no cells infected with the intÀ vector scored positive for GFP at FACS analysis, while the percentage of cells infected with the int+ lentivirus remained similar to that of 48 h (Figure 4b ). These two types of lentiviruses were then used for in vivo experiments. A volume of 200 ml of a 250 Â concentrated viral solution was injected into the left ventricle of rats while the pulmonary artery and aorta were being clamped during immersion hypothermia, as described in the Methods section. This procedure allows diffusion of the virus throughout the myocardium via the coronary arteries. GFP-positivity was analyzed on sections of myocardial tissue 5 weeks after treatment.
Results showed a sustained, diffuse transmural expression of GFP after 5 weeks in the myocardium of the group of rats (n¼3) treated with the int+ vector. In fact, most cardiomyocytes of int+ virus-infected rats, staining positive to MHC, expressed GFP, while GFP was absent in int-lentivirus-infected rats (n¼3) (Figure 4a ).
Discussion
Here, we report on the efficacy of a modified lentiviral vector as an easy and efficient way of inducing genes into the cardiomyocyte, both in vitro and in vivo. Our comparison of third-generation and 'advanced' lentiviral vectors demonstrates that the latter has an improved effect in transducing cardiomyocytes in vitro. Our data also describe the conditions of infection needed for optimal gene transduction in vitro, showing that 'advanced' lentiviral vectors induce a high percentage of GFP positivity in cardiomyocytes after only 2 h of exposure. Previous reports have shown that lentiviruses can infect neonatal rat cardiomyocytes in vitro. 6, 7 In one of these studies, a high percentage of infection was achieved, but the exact amount of virus needed for extensive infection was not specified. 7 In both cases, precise dosage and quantification of infection was not determined, nor was it assessed whether lentivirus induces extensive infection in vivo. In our hands, the third-generation lentivirus did not achieve satisfactory results, since the percentage of GFP-expressing cells was generally three-fold lower than that achieved with the 'advanced' generation vector, thus rendering impractical the use of this vector for studies requiring transduction of a high percentage of cardiomyocytes. On the other hand, 'advanced' generation lentiviral vectors were very efficient, transducing more than 80% of cells in vitro after 48 h with only one round of infection.
The differences observed between 'advanced' and third-generation lentiviruses lie in the 118 bp preceding the promoter region in the shuttle vector, as well as in the WPRE sequence at the 3 0 end of the expression cassette. Thus, even in this study these two elements have been shown to be critical in enhancing transduction efficiency.
We also used two different promoters, CMV and hPGK. A similar percentage of gene transduction was achieved with both, showing that either is suitable for studies in cardiomyocytes. It seems though, by analysis of MFI, that the expression driven by CMV is stronger than that of PGK.
Furthermore, the lack of expression seen in vivo with the int-variant of 'advanced' generation lentivirus strongly suggests that lentiviral DNA must be integrated with cardiomyocyte DNA in order to achieve a sustained and lasting expression in this cell type, as has been demonstrated also for other growth-arrested cells by Follenzi et al.
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In conclusion, the data reported in this work demonstrate that the 'advanced' generation lentiviral vector is an excellent cDNA carrier for cardiomyocytes, driving long-term gene expression both in vitro and in vivo. Since lentiviruses are not immunogenic, it is possible to foresee their use in myocardial gene therapy studies in the future.
Methods

Cell cultures
Neonatal rat cardiomyocytes were obtained utilizing a modification of an original protocol. [9] [10] [11] Cells were cultured in DMEM-Medium199 (4:1) supplemented with 5% FBS, 5% HS, 1% L-glutamine and 1% penicillin/ streptomycin. Cells were treated with Mitomycin C (Sigma) to prevent fibroblast cell growth. Final cell populations contained more than 95% growth-arrested cardiomyocytes, as assessed by immunofluorescence analysis.
293 T cells (originally called 293tsA1609ne 36 ) were grown in Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 10% FBS (Hyclone) and Lglutamine (50 U/ml), penicillin and streptomycin (50 U/ ml). 
Plasmids
The three-plasmid expression system used to generate lentiviral vectors by transient transfection was used as previously described. 5, 12 The three plasmids were: the packaging plasmid, pCMVDR8.74 designed to provide the HIV proteins needed to produce the virus particle; the envelope-coding plasmid, pMD.G, for pseudotyping the virion with VSV-G, and; the self-inactivating (SIN) transfer vector plasmid (pRRLcPPT.hPGK.EGFP.WPRE or pRRLcPPT.CMV.EGFP.WPRE). The transfer vector plasmid contains the enhanced GFP marker gene driven by either the human phosphoglycerate kinase promoter (hPGK) or the Cytomegalovirus promoter (CMV) and has been described before for assembling 'advanced' third-generation lentivirus. 5 It has an additional DNA sequence of 118 bp (cPPT) situated before the PGK/ CMV-EGFP cassette, taken from the pol gene, which has been shown to be required in cis. The third-generation transfer vector used for some experiments was pRRL.CMV.EGFP. This vector is identical to that of the 'advanced' generation apart from the absence of the cPPT and WPRE sequences.
Virus production
We produced vector stocks by calcium phosphate transient transfection, cotransfecting the three plasmids in 293 T human embryonic kidney cells, since these cells are good DNA recipients. The calcium phosphate-DNA precipitate was allowed to stay on the cells for 14-16 h, after which the medium was replaced, collected 48 h later, centrifuged at 1000 rpm for 5 min at room temperature and filtered through 0.22 mm pore nitrocellulose filters.
Determination of viral titer and transfection efficiency
In order to determine the viral particle concentration of the supernatants from 293 T cells, p24 antigen was analyzed by HIV-1 p24 Core profile ELISA (Abbott Diagnostics or NEN TM Life Science Products) following the manufacturer's instructions. Moreover, the supernatants were used to infect TF1 cells to determine biological efficiency before experimentation on cardiomyocytes. Transduction experiments were performed by adding serial dilutions of viral supernatant to 5 Â 10 4 TF1cells/well in 24-well plates in the presence of Polybrene (4 mg/ml). 7 TU/ml. Viral stocks were usually prepared at 10 6 TU/ml, corresponding to 100 ng p24/ml. Usually, cells were infected at a concentration of 5 Â 10 4 /ml, for non-saturating conditions or 2.5 Â 10 4 /ml, for saturating conditions, with a supernatant titer of 100 ng p24/ml. Relative mean fluorescence intensity (MFI) was calculated using FACS analysis parameters.
Concentration of viral supernatants
For in vivo experiments, the supernatant was concentrated 250-fold. To obtain high-titer vector stocks, medium collected from infected 293 T cells was ultracentrifuged at 50 000 g for 90 min at 41C. Pellets were resuspended with PBS containing 0.5% BSA, pooled and stored under liquid N 2 .
Transduction of cardiomyocytes
Cardiomyocytes were plated 2 days before exposure to the virus. Cells (2.5 Â 10 4 ) were plated in 24-well plates. On the day of infection, the medium was removed and replaced with viral supernatant to which 4 mg/ml of Polybrene had been added. Cells were then centrifuged in their plate for 45 min in a Beckman GS-6KR centrifuge, at 1800 rpm and 321C. After centrifugation, cells were kept for either 1 h 15 min or ON in a 5% CO 2 incubator at 32 or 371C, respectively. After exposure, cells were washed twice with cold PBS and fresh medium added. At either 12 or 48 h after the infection, cells were washed with PBS, harvested with trypsin/EDTA and analyzed by FACS.
Infection and detection of GFP in myocardial cells in vivo
For in vivo experiments, a preparation of the virus 250-fold more concentrated than the regular viral supernatant was used. A method based on that reported by Hajjar et al 13 and subsequently modified by Ikeda et al 14 was used to deliver the virus. The validity of the method was first determined by gene transduction using adenoviral b-galactosidase (not shown). Briefly, preliminary experiments were performed on male SpragueDawley rats (Charles River, Italy) anesthetized with a mixture of ketamine hydrochloride (Sigma, 50 mg/kg BW) and Xylazine (Sigma, 10 mg/kg BW), and then orally intubated and ventilated. The animals were subsequently cooled with ice-bags and their temperature monitored with a thermistor catheter. When the animal's temperature reached 301C, an anterior thoracotomy was performed, the heart was exteriorized and a 7.0 suture placed on the apex of the left ventricle. A 22 G catheter containing 200 ml of viral solution was then gently introduced into the left ventricle. The aortic root and pulmonary artery were identified and the catheter advanced through the left ventricle into the aortic root. The aorta and pulmonary artery were clamped gently, distal to the site of the catheter and the viral solution injected. The period of total occlusion (time for viral injection and the postinjection period) lasted 20 s, allowing the solution to circulate down the coronary arteries. Then the aortic and pulmonary clamps and the catheter were removed, the pneumothorax evacuated and the chest closed. Animals were transferred back to their cages where they were allowed to recover. The same procedure was followed for sham-operated rats, but the catheter was filled with saline.
The extension of b-galactosidase adenoviral infection was determined by 6Br-2-naphtyl-b-D-galactopyranoside/Fast Blue tissue staining after 15 days and compared to control. Most cells in the left ventricle showed blue granular condensations in the b-galactosidase infected hearts, which were absent in shamLentiviral gene transduction in cardiomyocytes D Bonci et al operated animals and in control sections (not shown). Similar experiments were also performed with a vital dye, demonstrating a uniform distribution of the dye throughout the myocardium (not shown).
